Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Mutations in the ret proto-oncogene and the von hippel-lindau disease tumour supressor gene in sporadic and syndromic phaeochromocytomas (1995)

  • Authors:
  • USP affiliated authors: TOLEDO, SERGIO PEREIRA DE ALMEIDA - FM
  • USP Schools: FM
  • DOI: 10.1136/jmg.32.12.934
  • Subjects: ENDOCRINOLOGIA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1136/jmg.32.12.934 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze
    Informações sobre o Citescore
  • Título: Journal of Medical Genetics

    ISSN: 0022-2593

    Citescore - 2017: 5.46

    SJR - 2017: 3.304

    SNIP - 2017: 1.788


  • How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ENG, C; CROSSEY, P A; MULLIGAN, L M; et al. Mutations in the ret proto-oncogene and the von hippel-lindau disease tumour supressor gene in sporadic and syndromic phaeochromocytomas. Journal of Medical Genetics, London, v. 32, n. 12, p. 934-7, 1995. DOI: 10.1136/jmg.32.12.934.
    • APA

      Eng, C., Crossey, P. A., Mulligan, L. M., Healey, C. S., Houghton, C., Prowse, A., et al. (1995). Mutations in the ret proto-oncogene and the von hippel-lindau disease tumour supressor gene in sporadic and syndromic phaeochromocytomas. Journal of Medical Genetics, 32( 12), 934-7. doi:10.1136/jmg.32.12.934
    • NLM

      Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PLM, Oriordan JLH, Toledo SPA, Smith DP, Maher ER. Mutations in the ret proto-oncogene and the von hippel-lindau disease tumour supressor gene in sporadic and syndromic phaeochromocytomas. Journal of Medical Genetics. 1995 ;32( 12): 934-7.
    • Vancouver

      Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PLM, Oriordan JLH, Toledo SPA, Smith DP, Maher ER. Mutations in the ret proto-oncogene and the von hippel-lindau disease tumour supressor gene in sporadic and syndromic phaeochromocytomas. Journal of Medical Genetics. 1995 ;32( 12): 934-7.

    Referências citadas na obra
    Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl lMed 1981;305:1617-27.
    Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Ferguson-Smith M. Clinical features and natural history of von Hippel-Lindau disease. QJ7Med 1990;77: 1151-63.
    Schimke R. Multiple endocrine neoplasia: how many syndromes? Am.7 Med Genet 1990;37:375-83.
    Eng C, Ponder BAJ. The role of gene mutations in the genesis of familial cancers. FASEB37 1993;7:910-9.
    Neumann HPH, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl _7 Med 1994;329: 1531-8.
    Atuk NO, McDonald T, Wood T, et al. Familial pheochromocytoma, hypercalcemia and von Hippel-Lindau disease: a ten year study of a larger family. Medicine (Baltimore) 1979;58:209-18.
    Neumann HPH. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 1987;16:220-6.
    Lamiell JM, Salazar FG, Hsia YE. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989;68: 1-29.
    Vasen HFA, Kruseman ACN, Berkel H, et al. Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration: a study of 15 kindreds in The Netherlands. Am.7 Med 1987;83:847-52.
    Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
    Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
    Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
    Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
    Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994;6:70-4.
    Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
    Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET protooncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-4 1.
    Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc NatlAcad Sci USA 1994;91:1579-83.
    Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET protooncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13.
    Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10: 2415-9.
    Mulligan LM, Marsh DJ, Robinson BG, et al. Genotypephenotype correlation in MEN 2: report of the International RET Mutation Consortium. _7 Intern Med (in press).
    Mathew CGP, Smith BA, Thorp K, et al. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 1987; 328:524-6.
    Mulligan LM, Eng C, Atti& T, et al. Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet 1994;3:2163-7.
    Kominoth P, Kunz E, Hiort 0, et al. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive singlestrand conformation polymorphism and direct sequencing. Am.7 Pathol 1994;145:922-9.
    Lindor NM, Honchel R, Khosla S, Thibodeau SN. Mutations in the RET protooncogene in sporadic pheochromocytomas.. Clin Endocrinol Metab 1995;80:627-9.
    Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, et al. The RET proto-oncogene in sporadic pheochromocytomas. Am _7 Hum Genet Suppl 1994;55:A51 (abstract 270).
    Dou S, Chi D, Carlson KM, Moley JA, Wells SA Jr, Donis-Keller H. RETproto-oncogene mutations associated with sporadic cases of medullary thyroid carcinoma. Fifth International Workshop on Multiple Endocnrne Neoplasia 1994: 73 (abstract 617).
    Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RETproto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994;3:1259-62.
    Eng C, Mulligan LM, Smith DP, et al. Mutations of the RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chrom Cancer 1995;12:209-12.
    Mulligan LM, Gardner E, Smith BA, Mathew CGP, Ponder BAJ. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chrom Cancer 1993;6: 166-77.
    Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
    Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor-suppressor gene in renal-carcinoma. Nature Genet 1994;7:85-90.
    WhaleyJM, NaglischJ, Gelbert L, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am _7 Hum Genet 1994;55: 1092-102.
    Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
    Feinberg A. A developmental context for multiple genetic alterations in Wilms' tumour. _7 Cell Sci 1994;S18:7-12.
    Crossey PA, Foster K, Richards FM, et al. Molecular genetic investigation of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994;93:53-8.
    Gutmann DH, Geist RT, Rose K, Goran W, Moley JF. Loss of neurofibromatosis type 1 (NFl) gene expression in pheochromocytomas from patients without NF 1. Genes Chrom Cancer 1995;13:104-9.